Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/17532368http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/17532368http://www.w3.org/2000/01/rdf-schema#comment"

Introduction

We have previously demonstrated platelet hyperreactivity in cystic fibrosis (CF) patients. Carriers of one CF mutation (heterozygotes) have been shown to have abnormalities related to the presence of only one-half the normal amount of CF transmembrane conductance regulator protein. Platelet hyperreactivity in CF heterozygotes would be an important cardiovascular risk factor, since approximately 1 in 25 Caucasians is a CF carrier.

Materials and methods

We used highly sensitive assays of platelet activation to assess the difference between 16 CF heterozygotes and 16 age- and sex-matched healthy controls without CF mutations.

Results

We found no difference in platelet activation between CF heterozygotes and controls.

Conclusions

The 50% reduction in the CF transmembrane conductance regulator protein in heterozygotes is insufficient to cause platelet activation."xsd:string
http://purl.uniprot.org/citations/17532368http://purl.org/dc/terms/identifier"doi:10.1016/j.thromres.2007.04.004"xsd:string
http://purl.uniprot.org/citations/17532368http://purl.uniprot.org/core/author"Li Y."xsd:string
http://purl.uniprot.org/citations/17532368http://purl.uniprot.org/core/author"Barnard M.R."xsd:string
http://purl.uniprot.org/citations/17532368http://purl.uniprot.org/core/author"Linden M.D."xsd:string
http://purl.uniprot.org/citations/17532368http://purl.uniprot.org/core/author"Michelson A.D."xsd:string
http://purl.uniprot.org/citations/17532368http://purl.uniprot.org/core/author"Fox M.L."xsd:string
http://purl.uniprot.org/citations/17532368http://purl.uniprot.org/core/author"O'Sullivan B.P."xsd:string
http://purl.uniprot.org/citations/17532368http://purl.uniprot.org/core/author"Frelinger A.L."xsd:string
http://purl.uniprot.org/citations/17532368http://purl.uniprot.org/core/author"Tarnow I."xsd:string
http://purl.uniprot.org/citations/17532368http://purl.uniprot.org/core/date"2007"xsd:gYear
http://purl.uniprot.org/citations/17532368http://purl.uniprot.org/core/name"Thromb Res"xsd:string
http://purl.uniprot.org/citations/17532368http://purl.uniprot.org/core/pages"159-162"xsd:string
http://purl.uniprot.org/citations/17532368http://purl.uniprot.org/core/title"Cystic fibrosis heterozygotes do not have increased platelet activation."xsd:string
http://purl.uniprot.org/citations/17532368http://purl.uniprot.org/core/volume"121"xsd:string
http://purl.uniprot.org/citations/17532368http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/17532368
http://purl.uniprot.org/citations/17532368http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/17532368
http://purl.uniprot.org/uniprot/#_A0A089NFM8-mappedCitation-17532368http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/17532368
http://purl.uniprot.org/uniprot/#_A0A089PPW6-mappedCitation-17532368http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/17532368
http://purl.uniprot.org/uniprot/#_A0A088T1A1-mappedCitation-17532368http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/17532368
http://purl.uniprot.org/uniprot/#_A0A096ZUB9-mappedCitation-17532368http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/17532368
http://purl.uniprot.org/uniprot/#_A0A096ZUC0-mappedCitation-17532368http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/17532368
http://purl.uniprot.org/uniprot/#_A0A096ZUC4-mappedCitation-17532368http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/17532368
http://purl.uniprot.org/uniprot/#_A0A096ZUH4-mappedCitation-17532368http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/17532368
▶